Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...

HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), ...

Psoriatic arthritis is a combination of psoriasis and arthritis symptoms. You may have skin and nail changes, joint pain and ...

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

Upadacitinib sustains its efficacy in non-radiographic axial spondyloarthritis through 2 years without presenting any new ...

Exercising, writing in a journal, taking pain relief medications, and joining a psoriatic arthritis support community could help you manage feelings of anxiety and improve your quality of life.